AOD-9604 the science.

AOD-9604 (“Anti-Obesity Drug 9604”) is a synthetic analog of the GH 176–191 lipolytic fragment, with a tyrosine added at the N-terminus to improve stability. It was investigated as a candidate compound for studying GH-associated fat metabolism without the growth and glucose effects of full-length growth hormone.

AOD-9604 has been evaluated in early human clinical studies, but it is not approved as a medicine for any indication. The material on this page is supplied strictly as a research peptide and is not an approved pharmaceutical product.

AOD-9604 research centers on the GH lipolytic domain:

• Lipolysis — stimulation of fat breakdown in adipocyte and animal models.
• Lipogenesis — reduced fat synthesis observed in some preclinical systems.
• Glucose neutrality — research examined whether the fragment’s metabolic activity occurs without the insulin-resistance effects associated with full-length GH.

AOD-9604 has both preclinical and early human research:

• Metabolic characterization (2000–2001). Studies described the synthetic lipolytic domain’s effects on lipid metabolism in cell and rodent models, including chronic-treatment work in obese and knockout mice.
• Human safety / tolerability. AOD-9604 was studied in early clinical trials for safety and tolerability in the obesity-research context; it did not advance to approval.
• Analytical work (2015). Detection and in-vitro metabolism studies were published in the anti-doping and analytical literature.

These human studies are early-phase and investigational. AOD-9604 is not FDA-approved, and this material is supplied for research use only.

AOD-9604 has preclinical evidence plus early human safety/tolerability data, but it is not FDA-approved and no approved indication, dosing, or therapeutic claim applies. AOD-9604 is supplied strictly as a research material — for research use only, not for human or veterinary use.